4412-59-3

Basic information

• Product Name: 17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one
• Synonyms: 13-Ethyl-17-hydroxy-18,19-dinorpregna-5(10),9(11)-dien-20-ynone;17-Ethinyl-17-hy-droxy-18-methylestra-5(10),9(11)-dien-3-one;17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one
• CAS NO: 4412-59-3
• Molecular Formula: C21H26O2
• Molecular Weight: 310.43
• Mol File: 4412-59-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one(4412-59-3)
• EPA Substance Registry System: 17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one(4412-59-3)

Safety Data

• Hazardous Substances Data: 4412-59-3(Hazardous Substances Data)

Usage

Description

17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one, also known as (17α)-13-Ethyl-17-hydroxy-18,19-dinorpregna-5(10),9(11)-dien-20-yn-3-one, is a chemical compound that serves as an intermediate in the synthesis of Gestrinone (G368800). Gestrinone is a steroidal antiestrogen, antiprogestogen, and an analog of Norgestrienone, with antigonadotropin properties. 17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one plays a crucial role in the development of pharmaceuticals targeting hormonal imbalances and related conditions.

Uses

Used in Pharmaceutical Industry:
17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one is used as an intermediate compound for the synthesis of Gestrinone, a steroidal antiestrogen and antiprogestogen, for the treatment of various hormonal imbalances and related conditions. Its role in the synthesis process is essential for creating a drug with potent antigonadotropin properties, which can be beneficial in managing conditions such as endometriosis, uterine fibroids, and certain types of cancer.
Additionally, due to its structural similarity to hormones, 17-Ethynyl-18-methylestra-5(10),9(11)-dien-17-ol-3-one may also be used in research and development for creating new drugs targeting hormone-related disorders, further expanding its applications in the pharmaceutical industry.